Optical Coherence Tomography And NEphropathy: The OCTANE Study

University of Edinburgh

Status

Enrolling

Conditions

Chronic Kidney Disease

Hypertension

Health

Study type

Observational

Funder types

Other

Identifiers

NCT02132741

14/SS/0069

Details and patient eligibility

About

Patients with high blood pressure (hypertension) and chronic kidney disease are at an increased risk of developing heart disease and strokes. Part of this risk is due to changes in the structure and function of the blood vessels throughout the body. It is thought that reducing high blood pressure and treating chronic kidney disease improves the structure and function of blood vessels but information on this is limited. Optical coherence tomography (OCT) is a method of looking at the blood vessels at the back of the eye. It is a simple, quick and non-invasive test that you may have previously had during a visit to the optician. The purpose of the study is to ascertain whether OCT is able to detect changes in the eye's blood vessels in patients with hypertension and chronic kidney disease compared to healthy individuals and also to see if any differences seen improve with treatment.

Full description

This project is an exploratory study, using enhanced depth imaging with the new SPECTRALIS OCT, designed to examine choroidal and microvascular retinal structure in patients with hypertension, chronic kidney disease (CKD), and in age and sex matched healthy controls. The study is non-invasive and takes only a few seconds to acquire these complex images. The Centre, where the images will be captured and where image analysis systems are located, is on the Royal Infirmary of Edinburgh (RIE) site close to the RIE outpatient clinics, making recruitment easy.

Enrollment

150 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male or female
Age 18-80
Body mass index ≤35
For those with hypertension: BP ≥140/90 or on treatment for hypertension
For those with CKD: CKD as defined by the Kidney Diseases Quality Initiative guidelines

Exclusion criteria

Subject is below the age of legal consent, or is mentally or legally incapacitated
The subject has donated blood (450 ml) within the last 4 weeks
Past or present drug or alcohol abuse including intravenous drug abuse at any time
Participation in another clinical trial within 1 month
Considered to be at high risk of HIV or hepatitis B
Patients with known eye disease, or previous eye surgery, or refractive error greater than +/- 6 dioptres.